Literature DB >> 18474676

UDP-glucuronosyltransferase 1A6 is the major isozyme responsible for protocatechuic aldehyde glucuronidation in human liver microsomes.

Hui-Xin Liu1, Yong Liu, Jiang-Wei Zhang, Wei Li, Hong-Tao Liu, Ling Yang.   

Abstract

Glucuronidation is an important pathway in the metabolism of protocatechuic aldehyde (3,4-dihydroxybenzaldehyde, PAL). However, the metabolites and primary UDP-glucuronosyltransferase (UGT) isozymes responsible for PAL glucuronidation remain to be determined in human. Here, we characterized PAL glucuronidation by human liver microsomes (HLMs), human intestine microsomes (HIMs), and 12 recombinant UGT (rUGT) isozymes to identify what kinds of metabolites are present and which human UGT isozymes are involved. Two metabolites (M-1 and M-2) were detected in reactions catalyzed by HLMs, HIMs, rUGT1A6, and rUGT1A9 and were identified as monoglucuronides by liquid chromatography-mass spectrometry. A kinetic study showed that PAL glucuronidation by rUGT1A6, rUGT1A9, HIMs, and HLMs followed Michaelis-Menten kinetics. The K(m) values of HLMs, HIMs, rUGT1A6, and rUGT1A9 for PAL glucuronidation were as follows: 432.7 +/- 24.5, 626.9 +/- 49.2, 367.5 +/- 25.1, and 379.9 +/- 42.5 microM for M-1 and 336.7 +/- 15.3, 494.3 +/- 48.7, 211.4 +/- 13.4, and 238.5 +/- 26.2 microM for M-2, respectively. The PAL glucuronidation activity was significantly correlated with UGT1A6 activity rather than with UGT1A9 activity from 15 individual HLMs. A chemical inhibition study showed that the IC(50) for phenylbutazone inhibition of PAL glucuronidation was similar in HLMs (61.9 +/- 7.9 microM) compared with rUGT1A6 (45.3 +/- 7.7 microM). In contrast, androsterone inhibited rUGT1A9-catalyzed and HLM-catalyzed PAL glucuronidation with IC(50) values of 27.1 +/- 3.8 and > 500 microM, respectively. In combination, we identified UGT1A6 as the major isozyme responsible for PAL glucuronidation in HLMs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474676     DOI: 10.1124/dmd.108.020560

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Characterization of nuciferine metabolism by P450 enzymes and uridine diphosphate glucuronosyltransferases in liver microsomes from humans and animals.

Authors:  Yan-liu LU; Yu-qi HE; Miao WANG; Li ZHANG; Li YANG; Zheng-tao WANG; Guang JI
Journal:  Acta Pharmacol Sin       Date:  2010-12       Impact factor: 6.150

2.  Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.

Authors:  Zhong-Ze Fang; Yan-Yan Zhang; Guang-Bo Ge; Hong Huo; Si-Cheng Liang; Ling Yang
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

3.  Characterization of cardamonin metabolism by P450 in different species via HPLC-ESI-ion trap and UPLC-ESI-quadrupole mass spectrometry.

Authors:  Yu-Qi He; Li Yang; Yong Liu; Jiang-Wei Zhang; Jun Tang; Juan Su; Yuan-Yuan Li; Yan-Liu Lu; Chang-Hong Wang; Ling Yang; Zheng-Tao Wang
Journal:  Acta Pharmacol Sin       Date:  2009-09-21       Impact factor: 6.150

4.  Regioselective Glucuronidation of Diosmetin and Chrysoeriol by the Interplay of Glucuronidation and Transport in UGT1A9-Overexpressing HeLa Cells.

Authors:  Xuejun Zeng; Jian Shi; Min Zhao; Qingwei Chen; Liping Wang; Huangyu Jiang; Feifei Luo; Lijun Zhu; Linlin Lu; Xinchun Wang; Zhongqiu Liu
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

5.  Identification of Human UDP-Glucuronosyltransferase 1A4 as the Major Isozyme Responsible for the Glucuronidation of 20(S)-Protopanaxadiol in Human Liver Microsomes.

Authors:  Jia Li; Chunyong He; Lianxiang Fang; Li Yang; Zhengtao Wang
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

6.  Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.

Authors:  E E J Kasteel; K Darney; N I Kramer; J L C M Dorne; L S Lautz
Journal:  Arch Toxicol       Date:  2020-05-15       Impact factor: 5.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.